- Systems, Pathways & Targets (SPT) The Systems, Pathways & Targets (SPT) Program is a newly formed program (created in 2011) that integrates cancer-focused members from two prior programs with new members who have expertise in the systems biology of cancer. SPT members focus on cellular signaling, tissue morphogenesis and computational modeling/bioinformatics. The overarching goal of this program is to identify key proteins or points of crosstalk for therapeutic intervention. To achieve this goal, three aims are proposed: 1) Identify key targets in signaling pathways, developmental pathways, and metabolic programs that are relevant to cancer initiation, progression, and therapeutic resistance, 2) Develop multi-disciplinary teams to study tumor heterogeneity and microenvironment/cellular interactions, 3) Diversify multi-disciplinary approaches to develop new therapeutic strategies. SPT members include cell biologists, immunologists, geneticists, developmental biologists, computational scientists, and clinicians. Dr. David Fruman and Dr. John Lowengrub direct the program as co- leaders. Their expertise in cellular signaling and drug development (Fruman) and systems biology of the tumor microenvironment (Lowengrub) embody the scientific breadth of basic research in the program, their partnering with basic and physician scientist members demonstrates the collaborative nature of SPT. Since the last renewal, exciting progress has been made in the identification of new targets in cancer cells and the development of small lead compounds against those targets. The first subset of these molecules are making their way to the bedside in the form of pre-clinical tests and clinical trials. Strategic partnering with members of the Chemical and Structural Biology (CSB) program has led to the synthesis of a second subset of molecules for evaluation in pre-clinical assays. In addition, SPT members have collaborated with bioengineers in the Onco-Imaging and Biotechnology (OIB) program for the development of new tools for cancer research. New collaborations with members of the Cancer Prevention, Outcomes and Survivorship (CPOS) program show promise in identifying and addressing issues in the catchment area of the cancer center. In the future, the SPT program leadership will continue to leverage the unique breadth and synergy among its members to build collaborative teams that tackle long-standing problems using bold and innovative approaches. Membership: 55 Members from 17 Departments Funding: $2,731,793 NCI (Totals); $9,767,626 Other Peer-Reviewed (Totals) Publications: 588 Publications, 15% Inter-programmatic; 12% Intra-programmatic

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Yu, James; Landberg, Jenny; Shavarebi, Farbod et al. (2018) Bioengineering triacetic acid lactone production in Yarrowia lipolytica for pogostone synthesis. Biotechnol Bioeng 115:2383-2388
Oliver, Andrew; Kay, Matthew; Cooper, Kerry K (2018) Comparative genomics of cocci-shaped Sporosarcina strains with diverse spatial isolation. BMC Genomics 19:310
Mahlbacher, Grace; Curtis, Louis T; Lowengrub, John et al. (2018) Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6:10
Neek, Medea; Tucker, Jo Anne; Kim, Tae Il et al. (2018) Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses. Biomaterials 156:194-203
McLelland, Bryce T; Lin, Bin; Mathur, Anuradha et al. (2018) Transplanted hESC-Derived Retina Organoid Sheets Differentiate, Integrate, and Improve Visual Function in Retinal Degenerate Rats. Invest Ophthalmol Vis Sci 59:2586-2603
Bota, Daniela A; Chung, Jinah; Dandekar, Manisha et al. (2018) Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol 7:CNS22
Han, Han; Qi, Ruxi; Zhou, Jeff Jiajing et al. (2018) Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction. Mol Cell 72:328-340.e8
Solares, Edwin A; Chakraborty, Mahul; Miller, Danny E et al. (2018) Rapid Low-Cost Assembly of the Drosophila melanogaster Reference Genome Using Low-Coverage, Long-Read Sequencing. G3 (Bethesda) 8:3143-3154
Wang, Yajun; Ngor, Arlene K; Nikoomanzar, Ali et al. (2018) Evolution of a General RNA-Cleaving FANA Enzyme. Nat Commun 9:5067
Qiu, Xiaolong; Lombardo, Jeremy A; Westerhof, Trisha M et al. (2018) Microfluidic filter device with nylon mesh membranes efficiently dissociates cell aggregates and digested tissue into single cells. Lab Chip 18:2776-2786

Showing the most recent 10 out of 1106 publications